SUNPHARMA Sun Pharmaceutical Industries Q2 FY26 results (Jul–Sep 2025) and concall
Sun Pharmaceutical Industries Limited reported a robust Q2 FY26, driven by strong growth in Global Innovative Medicines and India formulations. The company achieved significant sales and EBITDA growth, with margins expanding. Strategic investments in R&D and new product launches, particularly LEQSELVI and anticipated UNLOXCYT, are central to their future growth, despite a decline in the U.S. generics business.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 8.9%, net profit up 2.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 +9% |
| EBITDA | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 +15% |
| Net profit | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 +3% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
